ubmslateCN-logo-ubm

CN Mobile Logo

Search form

Topics:

ASCO 2016 Prostate Cancer

ASCO 2016 Prostate Cancer

Experimental, minimally invasive “liquid biopsy” blood tests might soon help to personalize prostate cancer treatment by predicting androgen resistance and survival benefits from particular treatments.

Use of multiparametric MRI could allow a significant portion of men with elevated PSA levels to avoid undergoing a biopsy without missing clinically significant prostate cancers.

Adding carboplatin to cabazitaxel was safe and associated with improved PFS among men with aggressive variant castration-resistant prostate cancer.

A hypofractionated shorter course of radiotherapy was not inferior to a conventional regimen in men with localized prostate cancer.

Cabazitaxel at two different doses was no better than docetaxel with regard to OS or PFS in men with metastatic castration-resistant prostate cancer.

An intermittent docetaxel regimen was non-inferior to continuous docetaxel therapy in patients with metastatic castration-resistant prostate cancer.

The addition of docetaxel to ADT offered decreased QOL at 3 months vs ADT alone, but better QOL at 12 months, in metastatic hormone-sensitive prostate cancer.

Pages

Subscribe to ASCO 2016 Prostate Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.